Exploration of the medical periodic table: towards new targets.

Metallodrugs offer potential for unique mechanisms of drug action based on the choice of the metal, its oxidation state, the types and number of coordinated ligands and the coordination geometry. We discuss recent progress in identifying new target sites and elucidating the mechanisms of action of anti-cancer, anti-bacterial, anti-viral, anti-parasitic, anti-inflammatory, and anti-neurodegenerative agents, as well as in the design of metal-based diagnostic agents. Progress in identifying and defining target sites has been accelerated recently by advances in proteomics, genomics and metal speciation analysis. Examples of metal compounds and chelating agents (enzyme inhibitors) currently in clinical use, clinical trials or preclinical development are highlighted.

[1]  Colin G. Barry,et al.  Platinum-intercalator conjugates: from DNA-targeted cisplatin derivatives to adenine binding complexes as potential modulators of gene regulation. , 2004, Current topics in medicinal chemistry.

[2]  C. Che,et al.  Gold(I) complex of N,N'-disubstituted cyclic thiourea with in vitro and in vivo anticancer properties-potent tight-binding inhibition of thioredoxin reductase. , 2010, Chemical communications.

[3]  J. Vincent.  Chromium: celebrating 50 years as an essential element? , 2010, Dalton transactions.

[4]  P. Dyson,et al.  Challenges and Opportunities in the Development of Organometallic Anticancer Drugs , 2012 .

[5]  Fang Yuan,et al.  Studies on characterization, telomerase inhibitory properties and G-quadruplex binding of η6-arene ruthenium complexes with 1,10-phenanthroline-derived ligands. , 2012, Dalton transactions.

[6]  K. Shudo,et al.  Potent estrogenic agonists bearing dicarba-closo-dodecaborane as a hydrophobic pharmacophore. , 1999, Journal of medicinal chemistry.

[7]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[8]  C. Leung,et al.  Cyclometalated platinum(II) complexes as topoisomerase IIα poisons. , 2011, Chemical communications.

[9]  P. Crouch,et al.  Therapeutic redistribution of metal ions to treat Alzheimer's disease. , 2012, Accounts of chemical research.

[10]  Corey W. Liu,et al.  Characterization of the FKBP.rapamycin.FRB ternary complex. , 2005, Journal of the American Chemical Society.

[11]  P. Sadler,et al.  Contrasting cellular uptake pathways for chlorido and iodido iminopyridine ruthenium arene anticancer complexes. , 2012, Metallomics : integrated biometal science.

[12]  Z. Trávníček,et al.  Anti-inflammatory active gold(I) complexes involving 6-substituted-purine derivatives. , 2012, Journal of medicinal chemistry.

[13]  T. Bastogne,et al.  Systems biology approach for in vivo photodynamic therapy optimization of ruthenium-porphyrin compounds. , 2012, Journal of photochemistry and photobiology. B, Biology.

[14]  F. Arjmand,et al.  Molecular drug design, synthesis and crystal structure determination of CuII-SnIV heterobimetallic core: DNA binding and cleavage studies. , 2012, European journal of medicinal chemistry.

[15]  L. Trent,et al.  Effects of chromium picolinate on body composition. , 1995, The Journal of sports medicine and physical fitness.

[16]  N. Farrell,et al.  Bis(platinum) complexes containing two platinum cis-diammine units. Synthesis and initial DNA-binding studies , 1988 .

[17]  A. Brandelli.  Nanostructures as promising tools for delivery of antimicrobial peptides. , 2012, Mini reviews in medicinal chemistry.

[18]  Shuaizhi Zheng,et al.  Therapeutic potential of photochemically active metal complexes based on interaction with enzymes. , 2012, Current topics in medicinal chemistry.

[19]  Stanley M Lemon,et al.  Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities. , 2009, Current opinion in pharmacology.

[20]  P. Sadler,et al.  Cytotoxicity, hydrophobicity, uptake, and distribution of osmium(II) anticancer complexes in ovarian cancer cells. , 2010, Journal of medicinal chemistry.

[21]  K. Şahin,et al.  Effects of chromium histidinate on renal function, oxidative stress, and heat-shock proteins in fat-fed and streptozotocin-treated rats. , 2010, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

[22]  T. Seki,et al.  Carbamoyl pyridone HIV-1 integrase inhibitors. 1. Molecular design and establishment of an advanced two-metal binding pharmacophore. , 2012, Journal of medicinal chemistry.

[23]  S. Fürst,et al.  Evaluation of Feasibility and Image Quality of 68Ga-DOTATOC Positron Emission Tomography/Magnetic Resonance in Comparison With Positron Emission Tomography/Computed Tomography in Patients With Neuroendocrine Tumors , 2013, Investigative radiology.

[24]  Sunil K. Sharma,et al.  Triplex mediated delivery of a platinum complex to a specific DNA target site. , 2004, Journal of inorganic biochemistry.

[25]  N. Farrell.  Polynuclear platinum drugs. , 2004, Metal ions in biological systems.

[26]  Chad A Mirkin,et al.  Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(IV) warheads. , 2009, Journal of the American Chemical Society.

[27]  Erik De Clercq,et al.  New anti‐HIV agents and targets , 2002, Medicinal research reviews.

[28]  B. Rosen,et al.  Transport pathways for arsenic and selenium: a minireview. , 2009, Environment international.

[29]  E. Meggers,et al.  Metal complex catalysis in living biological systems. , 2013, Chemical communications.

[30]  L. Ji,et al.  Studies on synthesis, characterization, and G-quadruplex binding of Ru(II) complexes containing two dppz ligands. , 2011, Journal of inorganic biochemistry.

[31]  A. Casini,et al.  Gold(I) carbene complexes causing thioredoxin 1 and thioredoxin 2 oxidation as potential anticancer agents. , 2012, Journal of medicinal chemistry.

[32]  S. Fürst,et al.  PET/MR: a paradigm shift , 2013, Cancer imaging : the official publication of the International Cancer Imaging Society.

[33]  R. Vilar,et al.  Interactions of ruthenium coordination cubes with DNA. , 2009, Dalton transactions.

[34]  Shailendra Singh,et al.  Cyclooctadiene Ru(II) complexes of thiophene-2-carboxaldehyde-derived thiosemicarbazones: synthesis, characterization and antiamoebic activity. , 2006, European journal of medicinal chemistry.

[35]  Xiao-da Yang,et al.  Synthesis, characterization and anti-diabetic therapeutic potential of a new benzyl acid-derivatized kojic acid vanadyl complex , 2012, BioMetals.

[36]  Anna F. A. Peacock,et al.  Organometallic osmium(II) arene anticancer complexes containing picolinate derivatives. , 2009, Inorganic chemistry.

[37]  J. Clardy,et al.  Borrowing to make ends meet. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[38]  H. Sigel,et al.  Metal complexes in tumor diagnosis and as anticancer agents , 2004 .

[39]  L. A. Basso,et al.  Isoniazid metal complex reactivity and insights for a novel anti-tuberculosis drug design , 2011, JBIC Journal of Biological Inorganic Chemistry.

[40]  P. Sadler,et al.  Metal complexes as DNA intercalators. , 2011, Accounts of chemical research.

[41]  V. Gandin,et al.  Synthesis and biological activity of ester- and amide-functionalized imidazolium salts and related water-soluble coinage metal N-heterocyclic carbene complexes. , 2012, Inorganic chemistry.

[42]  P. Hogg,et al.  The tumour metabolism inhibitors GSAO and PENAO react with cysteines 57 and 257 of mitochondrial adenine nucleotide translocase , 2012, Cancer Cell International.

[43]  D. Crowther,et al.  Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer. , 1988, European journal of cancer & clinical oncology.

[44]  B. Sarkar,et al.  Evidence for albumin--cu(II)--amino acid ternary complex. , 1968, Canadian journal of biochemistry.

[45]  Andrea F Armstrong,et al.  The bioinorganic and medicinal chemistry of carboranes: from new drug discovery to molecular imaging and therapy. , 2007, Dalton transactions.

[46]  P. Sadler,et al.  Thermochromic organometallic complexes: experimental and theoretical studies of 16- to 18-electron interconversions of adducts of arene Ru(II) carboranes with aromatic amine ligands. , 2013, Dalton transactions.

[47]  Gregory S. Smith,et al.  Targeted and multifunctional arene ruthenium chemotherapeutics. , 2011, Dalton transactions.

[48]  S. Fricker.  Metal complexes as therapeutic agents in nitrogen monoxide modulation. , 2004, Metal ions in biological systems.

[49]  S. Braga,et al.  Ru(II)-based antimicrobials: looking beyond organic drugs. , 2012, Mini reviews in medicinal chemistry.

[50]  P. Sadler,et al.  Anti-colorectal cancer activity of an organometallic osmium arene azopyridine complex , 2011 .

[51]  N. Farrell,et al.  A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts , 1999, British Journal of Cancer.

[52]  M. Sabat,et al.  Model for a platinated DNA triplex: Watson-Crick and metal-modified Hoogsteen pairing , 1992 .

[53]  A. Spek,et al.  A highly flexible dinuclear ruthenium(II)-platinum(II) complex: crystal structure and binding to 9-ethylguanine. , 2004, Angewandte Chemie.

[54]  S. Sinha,et al.  Chromium is not an essential trace element for mammals: effects of a “low-chromium” diet , 2011, JBIC Journal of Biological Inorganic Chemistry.

[55]  M. Harding,et al.  WATER SOLUBLE, HYDROLYTICALLY STABLE DERIVATIVES OF THE ANTITUMOR DRUG TITANOCENE DICHLORIDE AND BINDING STUDIES WITH NUCLEOTIDES , 1998 .

[56]  S. Uskoković-Marković,et al.  Insulin Mimetic Effect of Tungsten Compounds on Isolated Rat Adipocytes , 2010, Biological Trace Element Research.

[57]  Irene M. Baskerville-Abraham,et al.  Solution structures of a DNA dodecamer duplex with and without a cisplatin 1,2-d(GG) intrastrand cross-link: comparison with the same DNA duplex containing an oxaliplatin 1,2-d(GG) intrastrand cross-link. , 2007, Biochemistry.

[58]  S. Lippard,et al.  NMR solution structure of a DNA dodecamer duplex containing a cis-diammineplatinum(II) d(GpG) intrastrand cross-link, the major adduct of the anticancer drug cisplatin. , 1998, Biochemistry.

[59]  Erik De Clercq,et al.  Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers. , 2010, Pharmacology & therapeutics.

[60]  J. Rodríguez-Gil,et al.  Insulin-like actions of tungstate in diabetic rats. Normalization of hepatic glucose metabolism. , 1994, The Journal of biological chemistry.

[61]  C. Biot,et al.  The antimalarial ferroquine: from bench to clinic , 2011, Parasite.

[62]  W. Shepard,et al.  Crystal structure of a double-stranded DNA containing a cisplatin interstrand cross-link at 1.63 A resolution: hydration at the platinated site. , 1999, Nucleic acids research.

[63]  Hongzhe Sun,et al.  Biocoordination chemistry of bismuth : Recent advances , 2007 .

[64]  L. Juillerat-Jeanneret,et al.  Organometallic cages as vehicles for intracellular release of photosensitizers. , 2012, Journal of the American Chemical Society.

[65]  B. Nair,et al.  Effect of coordinated ligands on antiproliferative activity and DNA cleavage property of three mononuclear Cu(II)-terpyridine complexes. , 2012, European journal of medicinal chemistry.

[66]  P. Sadler,et al.  Kinetics of aquation and anation of ruthenium(II) arene anticancer complexes, acidity and X-ray structures of aqua adducts. , 2003, Chemistry.

[67]  Elias S. J. Arnér,et al.  Noble metal targeting of thioredoxin reductase--covalent complexes with thioredoxin and thioredoxin-related protein of 14 kDa triggered by cisplatin. , 2010, Free radical biology & medicine.

[68]  K. Dunbar,et al.  2D NMR spectroscopic evidence for unprecedented interactions of cis-[Rh2(dap)(mu-O2CCH3)2(eta1-O2CCH3)(CH3OH)](O2CCH3) with a DNA oligonucleotide: combination of intercalative and coordinative binding. , 2006, Angewandte Chemie.

[69]  P. Sadler,et al.  Influence of oxygenation on the reactivity of ruthenium-thiolato bonds in arene anticancer complexes: insights from XAS and DFT. , 2009, Journal of the American Chemical Society.

[70]  S. Lippard,et al.  Unwinding of supercoiled DNA by platinum-ethidium and related complexes , 1992 .

[71]  J. Barbet,et al.  Contribution of [64Cu]-ATSM PET in molecular imaging of tumour hypoxia compared to classical [18F]-MISO--a selected review. , 2011, Nuclear medicine review. Central & Eastern Europe.

[72]  A. Holmgren,et al.  Mercury and selenium interaction in vivo: effects on thioredoxin reductase and glutathione peroxidase. , 2012, Free radical biology & medicine.

[73]  J. Collins,et al.  Multi-nuclear platinum complexes as anti-cancer drugs , 2003 .

[74]  Robert Langer,et al.  Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA–PEG nanoparticles , 2008, Proceedings of the National Academy of Sciences.

[75]  M. Lim,et al.  Metal-associated amyloid-β species in Alzheimer's disease. , 2012, Current opinion in chemical biology.

[76]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[77]  H. Tamura,et al.  DNA Cleaving Activity and Cytotoxic Activity of Ferricenium Cations , 1997 .

[78]  P. Dyson,et al.  The "complex-in-a-complex" cations [(acac)2M subset Ru6(p-iPrC6H4Me)6(tpt)2(dhbq)3]6+: A trojan horse for cancer cells. , 2008, Angewandte Chemie.

[79]  P. Sadler,et al.  Structure-activity relationships for organometallic osmium arene phenylazopyridine complexes with potent anticancer activity. , 2011, Dalton transactions.

[80]  A. Bush.  Drug development based on the metals hypothesis of Alzheimer's disease. , 2008, Journal of Alzheimer's disease : JAD.

[81]  P. Dyson,et al.  Double targeting of tumours with pyrenyl-modified dendrimers encapsulated in an arene-ruthenium metallaprism. , 2011, Chemistry.

[82]  A. Ingle,et al.  Silver nanoparticles: the powerful nanoweapon against multidrug‐resistant bacteria , 2012, Journal of applied microbiology.

[83]  Xiaoping Yang,et al.  Insulin-sensitizing and cholesterol-lowering effects of chromium (D-Phenylalanine)3. , 2006, Journal of inorganic biochemistry.

[84]  Huifang Huang,et al.  Solution Structure of a Cisplatin-Induced DNA Interstrand Cross-Link , 1995, Science.

[85]  J. Humm,et al.  Targeted α particle immunotherapy for myeloid leukemia , 2002 .

[86]  Polypyridyl metal complexes with biological activity , 2011 .

[87]  D. Ribatti,et al.  Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A , 2002, British Journal of Cancer.

[88]  Stephen J Lippard,et al.  Structure of duplex DNA containing the cisplatin 1,2-{Pt(NH3)2}2+-d(GpG) cross-link at 1.77 A resolution. , 2010, Journal of inorganic biochemistry.

[89]  M. Telpoukhovskaia,et al.  Werner coordination chemistry and neurodegeneration. , 2013, Chemical Society reviews.

[90]  Sanjib Bhattacharyya,et al.  Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future. , 2012, Chemical Society reviews.

[91]  S. Monti,et al.  Tetra-2,3-pyrazinoporphyrazines with externally appended pyridine rings. 10. A water-soluble bimetallic (Zn(II)/Pt(II)) porphyrazine hexacation as potential plurimodal agent for cancer therapy: exploring the behavior as ligand of telomeric DNA G-quadruplex structures. , 2011, Inorganic chemistry.

[92]  P. Sadler,et al.  Targeted delivery of platinum-based anticancer complexes. , 2013, Current opinion in chemical biology.

[93]  P. Sadler,et al.  Anti-viral cyclam macrocycles : rapid zinc uptake at physiological pH. , 2004, Chemical communications.

[94]  H. Vogel.  Lactoferrin, a bird's eye view. , 2012, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[95]  I. Park,et al.  Effects of chromium picolinate supplementation on insulin sensitivity, serum lipids, and body weight in dexamethasone-treated rats. , 2002, Metabolism: clinical and experimental.

[96]  Rong Zhang,et al.  Stabilization of G-quadruplex DNA, inhibition of telomerase activity and live cell imaging studies of chiral ruthenium(II) complexes. , 2012, Chemistry.

[97]  Douglas D. Richman,et al.  Probing chelation motifs in HIV integrase inhibitors , 2012, Proceedings of the National Academy of Sciences.

[98]  V. Brabec,et al.  Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs. , 2005, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[99]  N. Farrell,et al.  Kinetic analysis of the stepwise formation of a long-range DNA interstrand cross-link by a dinuclear platinum antitumor complex: evidence for aquated intermediates and formation of both kinetically and thermodynamically controlled conformers. , 2001, Journal of the American Chemical Society.

[100]  E. Król,et al.  Chromium(III) propionate complex supplementation improves carbohydrate metabolism in insulin-resistance rat model. , 2010, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[101]  M. Zucchetti,et al.  Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[102]  E. De Pauw,et al.  Tridentate N-donor palladium(II) complexes as efficient coordinating quadruplex DNA binders. , 2011, Chemistry.

[103]  Synthesis, characterization, and antibacterial and anticancer screening of {M2+–Co3+–M2+} and {Co3+–M2+} (M is Zn, Cd, Hg) heterometallic complexes , 2012, JBIC Journal of Biological Inorganic Chemistry.

[104]  C. J. V. Garderen,et al.  The Solution Structure of a DNA Duplex Containing the cis ‐Pt(NH3)2[d(‐GTG‐)‐N 7(G), N 7(G)] Adduct, as Determined with High‐Field NMR and Molecular Mechanics/Dynamics , 1994 .

[105]  Hongzhe Sun.  Biological Chemistry of Arsenic, Antimony and Bismuth , 2010 .

[106]  E. Meggers.  From conventional to unusual enzyme inhibitor scaffolds: the quest for target specificity. , 2011, Angewandte Chemie.

[107]  N. Farrell,et al.  A third mode of DNA binding: Phosphate clamps by a polynuclear platinum complex. , 2006, Journal of the American Chemical Society.

[108]  P. Sadler,et al.  Designing organometallic compounds for catalysis and therapy. , 2012, Chemical communications.

[109]  P. Sadler,et al.  Dicarba-closo-dodecarborane-containing half-sandwich complexes of ruthenium, osmium, rhodium and iridium: biological relevance and synthetic strategies. , 2012, Chemical Society reviews.

[110]  J. Mccammon,et al.  Inhibition of cathepsin B by Au(I) complexes: a kinetic and computational study , 2008, JBIC Journal of Biological Inorganic Chemistry.

[111]  Wenting Wu,et al.  Encapsulation of hydrophobic pyrenyl­cycloplatinate complexes within a water-soluble arene ruthenium metalla­cage , 2012 .

[112]  Sanjay Singh,et al.  Exposure to Silver Nanoparticles Inhibits Selenoprotein Synthesis and the Activity of Thioredoxin Reductase , 2011, Environmental health perspectives.

[113]  D. Mansuy,et al.  Ferrocenyl quinone methides as strong antiproliferative agents: formation by metabolic and chemical oxidation of ferrocenyl phenols. , 2009, Angewandte Chemie.

[114]  Amit Kumar,et al.  Synthesis, spectroscopic characterization, insulin-enhancment, and competitive DNA binding activity of a new Zn(II) complex with a vitamin B6 derivative--a new fluorescence probe for Zn(II). , 2012, Dalton transactions.

[115]  D. Rehder.  The potentiality of vanadium in medicinal applications. , 2012, Future medicinal chemistry.

[116]  T. Sanchez,et al.  Ruthenium arene complexes as HIV-1 integrase strand transfer inhibitors. , 2013, Journal of inorganic biochemistry.

[117]  A. Eastman.  Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA. , 1986, Biochemistry.

[118]  P. J. Johnson.  Metronidazole and drug resistance. , 1993, Parasitology today.

[119]  M. Davies,et al.  Selenium‐containing amino acids as direct and indirect antioxidants , 2012, IUBMB life.

[120]  K. Suntharalingam,et al.  Synthesis, structural characterisation and quadruplex DNA binding studies of a new gold(III) pyrazolylpyridine complex. , 2010, Chemistry.

[121]  P. Dumy,et al.  Improvement of porphyrins for G-quadruplex DNA targeting. , 2011, Biochimie.

[122]  C. Che,et al.  Luminescent cyclometalated platinum(II) complexes containing N-heterocyclic carbene ligands with potent in vitro and in vivo anti-cancer properties accumulate in cytoplasmic structures of cancer cells , 2011 .

[123]  Laura Rodríguez,et al.  Phosphine-bridged dinuclear gold(I) alkynyl complexes: Thioredoxin reductase inhibition and cytotoxicity , 2013 .

[124]  P. Sadler,et al.  Trans,trans,trans-[PtIV(N3)2(OH)2(py)(NH3)]: A Light-Activated Antitumor Platinum Complex That Kills Human Cancer Cells by an Apoptosis-Independent Mechanism , 2012, Molecular Cancer Therapeutics.

[125]  J. Cummings,et al.  Inhibition of cancer cell growth by ruthenium(II) arene complexes. , 2001, Journal of medicinal chemistry.

[126]  W. Sundquist,et al.  DNA promotes the reaction of cis-diamminedichloroplatinum(II) with the exocyclic amino groups of ethidium bromide , 1988 .

[127]  D. Chan,et al.  Inhibition of Janus kinase 2 by cyclometalated rhodium complexes , 2012 .

[128]  Julie E Reed,et al.  Effect of metal coordination on the interaction of substituted phenanthroline and pyridine ligands with quadruplex DNA. , 2009, Dalton transactions.

[129]  D. Hibbs,et al.  The antimicrobial properties of some copper(II) and platinum(II) 1,10-phenanthroline complexes. , 2013, Dalton transactions.

[130]  M. Jakupec,et al.  Osmium(II)--versus ruthenium(II)--arene carbohydrate-based anticancer compounds: similarities and differences. , 2010, Dalton transactions.

[131]  S. Donnini,et al.  Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers , 2003, British Journal of Cancer.

[132]  U. Bierbach,et al.  Interactions of a platinum-modified perylene derivative with the human telomeric G-quadruplex. , 2011, The journal of physical chemistry. B.

[133]  T. A. Connors,et al.  Structure and activity relationships of platinum complexes with anti-tumour activity. , 1975, Chemico-biological interactions.

[134]  J. Pope,et al.  Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists. , 2002, The Journal of rheumatology.

[135]  J. Marrot,et al.  Synthesis and Structure Activity Relationship of Organometallic Steroidal Androgen Derivatives , 2009 .

[136]  Karl-Peter Hopfner,et al.  Bypass of DNA Lesions Generated During Anticancer Treatment with Cisplatin by DNA Polymerase η , 2007, Science.

[137]  W. Berger,et al.  Anticancer activity of metal complexes: involvement of redox processes. , 2011, Antioxidants & redox signaling.

[138]  J. Furrer,et al.  Interaction of a ruthenium hexacationic prism with amino acids and biological ligands: ESI mass spectrometry and NMR characterisation of the reaction products , 2012, JBIC Journal of Biological Inorganic Chemistry.

[139]  Christian G Hartinger,et al.  Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology. , 2006, Chemical reviews.

[140]  Xiangyang Liang,et al.  Structure and dynamics of metallomacrocycles: recognition of zinc xylyl-bicyclam by an HIV coreceptor. , 2002, Journal of the American Chemical Society.

[141]  S. Lippard,et al.  Structure, Recognition, and Processing of Cisplatin-DNA Adducts. , 1999, Chemical reviews.

[142]  Jody M. Havener,et al.  NMR solution structure of an oxaliplatin 1,2-d(GG) intrastrand cross-link in a DNA dodecamer duplex. , 2004, Journal of molecular biology.

[143]  J. Yeow,et al.  Antibacterial properties of poly(quaternary ammonium) modified gold and titanium dioxide nanoparticles. , 2012, Journal of nanoscience and nanotechnology.

[144]  P. Dyson,et al.  Anticancer activity of osmium metalla-rectangles. , 2010, Dalton transactions.

[145]  W. Berger,et al.  KP1019, A New Redox‐Active Anticancer Agent – Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients , 2008, Chemistry & biodiversity.

[146]  P. Ell,et al.  Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors , 2013, The Journal of Nuclear Medicine.

[147]  K. Suntharalingam,et al.  Two metals are better than one: investigations on the interactions between dinuclear metal complexes and quadruplex DNA. , 2010, Inorganic chemistry.

[148]  A. Vargiu,et al.  Detecting DNA mismatches with metallo-insertors: a molecular simulation study. , 2012, Inorganic chemistry.

[149]  J. Cowan,et al.  Catalytic metallodrugs targeting HCV IRES RNA. , 2012, Chemical communications.

[150]  Z. Rehman,et al.  Synthesis, characterization and anticancer studies of mixed ligand dithiocarbamate palladium(II) complexes. , 2011, European journal of medicinal chemistry.

[151]  P. Dyson,et al.  Enzyme inhibition by metal complexes: concepts, strategies and applications , 2013 .

[152]  Anna F. A. Peacock,et al.  Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions. , 2006, Journal of the American Chemical Society.

[153]  G. Gasser,et al.  Organometallic Anticancer Compounds , 2010, Journal of medicinal chemistry.

[154]  A. Casini,et al.  Organometallic ruthenium(II) arene compounds with antiangiogenic activity. , 2011, Journal of medicinal chemistry.

[155]  P. Dyson,et al.  A ruthenium antimetastasis agent forms specific histone protein adducts in the nucleosome core. , 2011, Chemistry.

[156]  L. Marzilli,et al.  Relationship of solution and protein-bound structures of DNA duplexes with the major intrastrand cross-link lesions formed on cisplatin binding to DNA. , 2001, Journal of the American Chemical Society.

[157]  Laura Clément,et al.  Toxicity of TiO(2) nanoparticles to cladocerans, algae, rotifers and plants - effects of size and crystalline structure. , 2013, Chemosphere.

[158]  U. Schatzschneider.  PhotoCORMs: Light-triggered release of carbon monoxide from the coordination sphere of transition metal complexes for biological applications , 2011 .

[159]  D. Scheinberg,et al.  Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[160]  K. Blennow,et al.  PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. , 2010, Journal of Alzheimer's disease : JAD.

[161]  Jim A. Thomas,et al.  Synthesis, characterization, and DNA binding properties of ruthenium(II) complexes containing the redox active ligand benzo[i]dipyrido[3,2-a:2',3'-c]phenazine-11,16-quinone. , 2012, Inorganic chemistry.

[162]  W. Feng,et al.  Comparing anti-hyperglycemic activity and acute oral toxicity of three different trivalent chromium complexes in mice. , 2012, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[163]  P. Sadler,et al.  Competitive Binding of Bismuth to Transferrin and Albumin in Aqueous Solution and in Blood Plasma* , 2001, The Journal of Biological Chemistry.

[164]  E. Beauchamp,et al.  A new era for an ancient drug: arsenic trioxide and Hedgehog signaling. , 2012, Vitamins and hormones.

[165]  D. Chan,et al.  A cyclometallated iridium(III) complex as a c-myc G-quadruplex stabilizer and down-regulator of c-myc oncogene expression. , 2013, Current medicinal chemistry.

[166]  P. Junk,et al.  Bismuth(III) Thiobenzoates and their Activity against Helicobacter pylori , 2012 .

[167]  Francesco Zerbetto,et al.  In Silico Carborane Docking to Proteins and Potential Drug Targets , 2011, J. Chem. Inf. Model..

[168]  M. Tong,et al.  Platinum squares with high selectivity and affinity for human telomeric G-quadruplexes. , 2012, Chemical communications.

[169]  E. De Clercq,et al.  Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. , 1997, Antiviral research.

[170]  Ronen Marmorstein,et al.  Targeting large kinase active site with rigid, bulky octahedral ruthenium complexes. , 2008, Journal of the American Chemical Society.

[171]  M. Riccioni,et al.  Update on triple therapy for eradication of Helicobacter pylori : current status of the art , 2012 .

[172]  S. Ralph.  Arsenic-Based Antineoplastic Drugs and Their Mechanisms of Action , 2008, Metal-based drugs.

[173]  B. Sarkar,et al.  Neuromedin C binds Cu(II) and Ni(II) via the ATCUN motif: implications for the CNS and cancer growth. , 1995, Biochemical and biophysical research communications.

[174]  Hideo Araki,et al.  Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. , 2003, Cancer research.

[175]  G. Gale,et al.  Cis-dichlorodiammineplatinum (II). Persistent and selective inhibition of deoxyribonucleic acid synthesis in vivo. , 1970, Biochemical pharmacology.

[176]  B. Chauffert,et al.  Discrepancy between in vitro and in vivo antitumor effect of a new platinum(II) metallointercalator , 2011, Investigational New Drugs.

[177]  Katherine S. Lovejoy,et al.  cis-Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects , 2008, Proceedings of the National Academy of Sciences.

[178]  N. Kröger,et al.  Phase II Clinical Trial of Titanocene Dichloride in Patients with Metastatic Breast Cancer , 2000, Oncology Research and Treatment.

[179]  N. Farrell,et al.  Long range 1,4 and 1,6-interstrand cross-links formed by a trinuclear platinum complex. Minor groove preassociation affects kinetics and mechanism of cross-link formation as well as adduct structure. , 2004, Journal of the American Chemical Society.

[180]  R. Perez,et al.  Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule. , 1994, Cancer research.

[181]  Y. Zou,et al.  Effects of geometric isomerism and ligand substitution in bifunctional dinuclear platinum complexes on binding properties and conformational changes in DNA. , 1995, Biochemistry.

[182]  C. Biot,et al.  Investigation of the redox behavior of ferroquine, a new antimalarial. , 2008, Molecular pharmaceutics.

[183]  P. Hogg,et al.  Pharmaceutical development of the novel arsenical based cancer therapeutic GSAO for Phase I clinical trial. , 2012, International journal of pharmaceutics.

[184]  P. Sadler,et al.  Competition between glutathione and guanine for a ruthenium(II) arene anticancer complex: detection of a sulfenato intermediate. , 2005, Journal of the American Chemical Society.

[185]  P. Sadler,et al.  Organometallic osmium arene complexes with potent cancer cell cytotoxicity. , 2010, Journal of medicinal chemistry.

[186]  P. Sadler,et al.  Diversity in guanine-selective DNA binding modes for an organometallic ruthenium arene complex. , 2006, Angewandte Chemie.

[187]  P. Sadler,et al.  Organometallic ruthenium and iridium transfer-hydrogenation catalysts using coenzyme NADH as a cofactor. , 2012, Angewandte Chemie.

[188]  A. Prokop,et al.  The role of the intrinsic FAS pathway in Titanocene Y apoptosis: The mechanism of overcoming multiple drug resistance in malignant leukemia cells. , 2012, Toxicology in vitro : an international journal published in association with BIBRA.

[189]  R. Webster,et al.  Similar biological activities of two isostructural ruthenium and osmium complexes. , 2008, Chemistry.

[190]  J. Collins,et al.  Multi-nuclear platinum drugs: a new paradigm in chemotherapy. , 2005, Current medicinal chemistry. Anti-cancer agents.

[191]  C. He,et al.  Synthesis and biological studies of 4', 7, 8-trihydroxy-isoflavone metal complexes. , 2011, Journal of inorganic biochemistry.

[192]  R. Gomis,et al.  Phosphorylation events implicating p38 and PI3K mediate tungstate-effects in MIN6 beta cells. , 2007, Biochemical and biophysical research communications.

[193]  A. Tramontano,et al.  Investigation of a potential mechanism for the inhibition of SmTGR by Auranofin and its implications for Plasmodium falciparum inhibition. , 2012, Biochemical and biophysical research communications.

[194]  J. Flohr,et al.  Chromium Nicotinate Supplementation , 1997 .

[195]  K. Suntharalingam,et al.  Synthesis, structural characterization, and quadruplex DNA binding studies of platinum(II)-terpyridine complexes. , 2009, Inorganic chemistry.

[196]  C. Biot,et al.  Ferroquine, an Ingenious Antimalarial Drug –Thoughts on the Mechanism of Action , 2008, Molecules.

[197]  K. Barnham,et al.  Alzheimer's disease & metals: therapeutic opportunities , 2011, British journal of pharmacology.

[198]  R. Abagyan,et al.  A metal-based inhibitor of tumor necrosis factor-α. , 2012, Angewandte Chemie.

[199]  R. Gust,et al.  NHC gold halide complexes derived from 4,5-diarylimidazoles: synthesis, structural analysis, and pharmacological investigations as potential antitumor agents. , 2011, Journal of medicinal chemistry.

[200]  C. Bagowski,et al.  Iridium complex with antiangiogenic properties. , 2010, Angewandte Chemie.

[201]  H. Maeda.  The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.

[202]  N. Farrell,et al.  Excursions in polynuclear platinum DNA binding. , 2010, Chemical communications.

[203]  R. Foresti,et al.  Therapeutic applications of carbon monoxide-releasing molecules , 2005, Expert opinion on investigational drugs.

[204]  Carmen Mejía,et al.  Potential cytotoxic and amoebicide activity of first row transition metal compounds with 2,9-bis-(2',5'-diazahexanyl)-1,1-phenanthroline (L1). , 2012, Dalton transactions.

[205]  P. Sadler,et al.  Ruthenium(II) arene anticancer complexes with redox-active diamine ligands. , 2009, Inorganic chemistry.

[206]  G. Barone,et al.  (Dipyrido[3,2-a:2',3'-c]phenazine)(glycinato)copper(II) perchlorate: a novel DNA-intercalator with anti-proliferative activity against thyroid cancer cell lines. , 2012, Journal of inorganic biochemistry.

[207]  Simon Parsons,et al.  Protein recognition of macrocycles: binding of anti-HIV metallocyclams to lysozyme. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[208]  D. Taramelli,et al.  Insights into the mechanism of action of ferroquine. Relationship between physicochemical properties and antiplasmodial activity. , 2005, Molecular pharmaceutics.

[209]  A. Casini,et al.  Molecular mechanisms and proposed targets for selected anticancer gold compounds. , 2011, Current topics in medicinal chemistry.

[210]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[211]  H. Sperling,et al.  Phase II trial of titanocene dichloride in advanced renal-cell carcinoma , 1998, Cancer Chemotherapy and Pharmacology.

[212]  L. Ji,et al.  Visual specific luminescent probing of hybrid G-quadruplex DNA by a ruthenium polypyridyl complex. , 2012, Chemical communications.

[213]  Anna F. A. Peacock,et al.  Osmium(II) and ruthenium(II) arene maltolato complexes: rapid hydrolysis and nucleobase binding. , 2007, Chemistry.

[214]  S. Lippard,et al.  Consequences of cisplatin binding on nucleosome structure and dynamics. , 2010, Chemistry & biology.

[215]  A. Vessières,et al.  Selective estrogen receptor modulators in the ruthenocene series. Synthesis and biological behavior. , 2005, Journal of medicinal chemistry.

[216]  Eric Meggers,et al.  Exploring biologically relevant chemical space with metal complexes. , 2007, Current opinion in chemical biology.

[217]  H. C. Harder,et al.  Inhibitory effects of anti‐tumor platinum compounds on DNA, RNA and protein syntheses in mammalian cells in vitro , 1970, International journal of cancer.

[218]  R. Neri,et al.  Anti-androgenicity of flutamide and its metabolite Sch 16423. , 1979, Biochemical Society transactions.

[219]  P. Dyson,et al.  Antiproliferative activity of chelating N,O- and N,N-ruthenium(II) arene functionalised poly(propyleneimine) dendrimer scaffolds. , 2011, Dalton transactions.

[220]  Huilu Wu,et al.  Synthesis, structure, DNA-binding properties and antioxidant activity of silver(I) complexes containing V-shaped bis-benzimidazole ligands. , 2012, Dalton transactions.

[221]  S. Wölfl,et al.  Benzimidazol-2-ylidene gold(I) complexes are thioredoxin reductase inhibitors with multiple antitumor properties. , 2010, Journal of medicinal chemistry.

[222]  T. Ganesan,et al.  Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[223]  S. Wölfl,et al.  Comparative in vitro evaluation of N-heterocyclic carbene gold(I) complexes of the benzimidazolylidene type. , 2011, Journal of medicinal chemistry.

[224]  P. Sadler,et al.  Photocontrolled DNA binding of a receptor-targeted organometallic ruthenium(II) complex. , 2011, Journal of the American Chemical Society.

[225]  P. Sadler,et al.  DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media. , 2003, Biochemistry.

[226]  B. Jiang,et al.  Helicobacter pylori Eradication with Ecabet Sodium, Omeprazole, Amoxicillin, and Clarithromycin Versus Bismuth, Omeprazole, Amoxicillin, and Clarithromycin Quadruple Therapy: A Randomized, Open‐Label, Phase IV Trial , 2012, Helicobacter.

[227]  T. Wohlschlager,et al.  Chemo-genetic optimization of DNA recognition by metallodrugs using a presenter-protein strategy. , 2010, Chemistry.

[228]  Irene M. Baskerville-Abraham,et al.  Flanking Bases Influence the Nature of DNA Distortion by Platinum 1,2-Intrastrand (GG) Cross-Links , 2011, PloS one.

[229]  V. Brabec,et al.  DNA modifications by a novel bifunctional trinuclear platinum phase I anticancer agent. , 1999, Biochemistry.

[230]  E. Mintz,et al.  Chelation therapy in Wilson's disease: from D-penicillamine to the design of selective bioinspired intracellular Cu(I) chelators. , 2012, Dalton transactions.

[231]  N. Dharmaraj,et al.  Evaluation of DNA binding, DNA cleavage, protein binding and in vitro cytotoxic activities of bivalent transition metal hydrazone complexes. , 2011, European journal of medicinal chemistry.

[232]  R. Gust,et al.  Photoinduced CO release, cellular uptake and cytotoxicity of a tris(pyrazolyl)methane (tpm) manganese tricarbonyl complex. , 2008, Chemical communications.

[233]  Hongjuan Lu,et al.  Inhibition of glutathione synthesis eliminates the adaptive response of ascitic hepatoma 22 cells to nedaplatin that targets thioredoxin reductase. , 2012, Toxicology and applied pharmacology.

[234]  C. Leung,et al.  Stable anticancer gold(III)-porphyrin complexes: effects of porphyrin structure. , 2010, Chemistry.

[235]  M. Gumpel,et al.  Osmic acid revisited: factors that predict a favourable response. , 2003, Rheumatology.

[236]  P. Dyson,et al.  Evidence for drug release from a metalla-cage delivery vector following cellular internalisation. , 2010, Chemistry.

[237]  Anna F. A. Peacock,et al.  Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O-chelating ligands to achieve cancer cell cytotoxicity. , 2007, Journal of the American Chemical Society.

[238]  A. Mouzaki,et al.  Anti-TNF-α Antibody Therapies in Autoimmune Diseases , 2006 .

[239]  P. McGowan,et al.  Functionalized Cyclopentadienyl Titanium Organometallic Compounds as New Antitumor Drugs , 2004 .

[240]  S. Wölfl,et al.  Evaluation of arene ruthenium(II) N-heterocyclic carbene complexes as organometallics interacting with thiol and selenol containing biomolecules. , 2013, Dalton transactions.

[241]  Wen-Qi Jiang,et al.  Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results. , 2013, International journal of clinical pharmacology and therapeutics.

[242]  S. Agarwal,et al.  Synthesis and Anti‐Amoebic Activity of Gold(I), Ruthenium(II), and Copper(II) Complexes of Metronidazole , 2005, Chemistry & biodiversity.

[243]  P. Sadler,et al.  Photoactivatable platinum complexes. , 2007, Anti-cancer agents in medicinal chemistry.

[244]  Stephen J Archibald,et al.  Configurationally restricted bismacrocyclic CXCR4 receptor antagonists. , 2006, Journal of medicinal chemistry.

[245]  P. Sadler,et al.  Tryptophan switch for a photoactivated platinum anticancer complex. , 2012, Journal of the American Chemical Society.

[246]  John D. Roberts,et al.  Cellular pharmacology of polynuclear platinum anti-cancer agents. , 1999, Journal of inorganic biochemistry.

[247]  L. Flohé,et al.  The thiol‐based redox networks of pathogens: Unexploited targets in the search for new drugs , 2006, BioFactors.

[248]  P. Sadler,et al.  Decomposition pathways for the photoactivated anticancer complex cis,trans,cis-[Pt(N3)2(OH)2(NH3)2]: insights from DFT calculations. , 2009, Physical chemistry chemical physics : PCCP.

[249]  J. C. Lima,et al.  Phosphine-gold(I) compounds as anticancer agents: general description and mechanisms of action. , 2011, Anti-cancer agents in medicinal chemistry.

[250]  P. Dyson,et al.  Bioanalytical and biophysical techniques for the elucidation of the mode of action of metal-based drugs. , 2011, Current topics in medicinal chemistry.

[251]  G. Parkinson,et al.  Molecular basis of structure-activity relationships between salphen metal complexes and human telomeric DNA quadruplexes. , 2012, Journal of medicinal chemistry.

[252]  P. Sadler,et al.  Differences in the cellular response and signaling pathways between cisplatin and monodentate organometallic Ru(II) antitumor complexes containing a terphenyl ligand. , 2011, Molecular pharmaceutics.

[253]  B. Therrien,et al.  Encapsulation of pyrene-functionalized poly(benzyl ether) dendrons into a water-soluble organometallic cage. , 2011, Chemistry, an Asian journal.

[254]  R. Ronimus,et al.  The composition of Ehrlich's salvarsan: resolution of a century-old debate. , 2005, Angewandte Chemie.

[255]  S. Larson,et al.  Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia , 2010, Clinical Cancer Research.

[256]  P. Sadler,et al.  Metal and ligand control of sulfenate reactivity: arene ruthenium thiolato-mono-S-oxides. , 2008, Angewandte Chemie.

[257]  D. Finkelstein,et al.  Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[258]  T. Kruck,et al.  A peptide molecule mimicking the copper(II) transport site of human serum albumin. A comparative study between the synthetic site and albumin. , 1974, The Journal of biological chemistry.

[259]  R. Lopez,et al.  Development of nitrosyl ruthenium complex-loaded lipid carriers for topical administration: improvement in skin stability and in nitric oxide release by visible light irradiation. , 2010, Journal of pharmaceutical and biomedical analysis.

[260]  B. Keppler,et al.  Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry , 2010, JBIC Journal of Biological Inorganic Chemistry.

[261]  C. Fang,et al.  A newly synthetic chromium complex – chromium(phenylalanine)3 improves insulin responsiveness and reduces whole body glucose tolerance , 2005, FEBS letters.

[262]  A. Budimir.  Metal ions, Alzheimer's disease and chelation therapy , 2011, Acta pharmaceutica.

[263]  Ke-Zhi Wang,et al.  Synthesis, pH-induced "on-off-on" luminescence switching, and partially intercalative DNA-binding and DNA photocleavage properties of an β-D-allopyranoside-grafted ruthenium(II) complex. , 2012, Journal of inorganic biochemistry.

[264]  Xiaole Kong,et al.  Design of iron chelators with therapeutic application. , 2012, Dalton transactions.

[265]  G. Boscutti,et al.  t-Butylsarcosinedithiocarbamato gold(III)-based anticancer agents: Design, in vitro biological evaluation and interaction with model biomolecules , 2012 .

[266]  D. Bajuk-Bogdanović,et al.  Sectroscopic study of stability and molecular species of 12-tungstophosphoric acid in aqueous solution , 2008 .

[267]  C. Pabo,et al.  Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins , 1999, Nature.

[268]  D. Herebian,et al.  Coligand tuning of the DNA binding properties of bioorganometallic (η6-arene)ruthenium(II) complexes of the type [(η6-arene)Ru(amino acid)(dppz)]n+ (dppz = dipyrido[3,2-a:2′,3′-c]phenazine), n = 1–3 , 2002 .

[269]  H. Tucker,et al.  Nonsteroidal antiandrogens. Synthesis and structure-activity relationships of 3-substituted derivatives of 2-hydroxypropionanilides. , 1988, Journal of medicinal chemistry.

[270]  Eric Meggers,et al.  Targeting proteins with metal complexes. , 2009, Chemical communications.

[271]  J. Roberts,et al.  Interactions between mammalian cell DNA and inorganic platinum compounds. II. Interstrand cross-linking of isolated and cellular DNA by platinum(IV) compounds. , 1974, Biochemical pharmacology.

[272]  S. Berners‐Price,et al.  Mitochondria-targeted chemotherapeutics: the rational design of gold(I) N-heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to thiols. , 2008, Journal of the American Chemical Society.

[273]  H. Beraldo,et al.  Spectroscopic and electrochemical characterization of gold(I) and gold(III) complexes with glyoxaldehyde bis(thiosemicarbazones): cytotoxicity against human tumor cell lines and inhibition of thioredoxin reductase activity , 2012, BioMetals.

[274]  G. Gasser,et al.  Small organometallic compounds as antibacterial agents. , 2012, Dalton transactions.

[275]  B. Van Houten,et al.  Chemical reactivity and DNA sequence specificity of formally monofunctional and bifunctional bis(platinum) complexes. , 1994, Journal of inorganic biochemistry.

[276]  M. Costantini,et al.  Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project. , 1991, The Journal of urology.

[277]  I. Viano,et al.  A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system. , 1999, Molecular pharmacology.

[278]  Ronald L. Bruening,et al.  Thermodynamic and kinetic data for macrocycle interactions with cations and anions , 1991 .

[279]  A. Vessières,et al.  Ferrocenyl catechols: synthesis, oxidation chemistry and anti-proliferative effects on MDA-MB-231 breast cancer cells. , 2012, Dalton transactions.

[280]  D. Lydall,et al.  Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. , 1986, Cancer research.

[281]  P. Sadler,et al.  Organometallic ruthenium(II) diamine anticancer complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts. , 2002, Journal of the American Chemical Society.

[282]  A. Mittermaier,et al.  Platinum(II) Phenanthroimidazoles for Targeting Telomeric G‐Quadruplexes , 2012, ChemMedChem.

[283]  M. Arkin,et al.  A high throughput drug screen for Entamoeba histolytica identifies a new lead and target , 2012, Nature Medicine.

[284]  R. Leapman,et al.  Elemental composition of secretory granules in pancreatic islets of Langerhans. , 1993, Biophysical journal.

[285]  Dugganna Girija,et al.  Synthesis, DNA Binding, and Cleavage Studies of Co(III) Complexes with Fused Aromatic NO/NN-Containing Ligands , 2012, Nucleosides, nucleotides & nucleic acids.

[286]  Andrew J. P. White,et al.  A cyclometallated platinum complex as a selective optical switch for quadruplex DNA. , 2012, Chemistry.

[287]  K. P. Bhabak,et al.  Bioinorganic and medicinal chemistry: aspects of gold(I)-protein complexes. , 2011, Dalton transactions.

[288]  L. Spiccia,et al.  Molecular and cellular characterization of the biological effects of ruthenium(II) complexes incorporating 2-pyridyl-2-pyrimidine-4-carboxylic acid. , 2012, Journal of the American Chemical Society.

[289]  Bernhard Lippert,et al.  Cisplatin : chemistry and biochemistry of a leading anticancer drug , 2006 .

[290]  Mei Han,et al.  DNA- and RNA-binding and enhanced DNA-photocleavage properties of a ferrocenyl-containing ruthenium(II) complex. , 2012, Journal of inorganic biochemistry.

[291]  S. Shen,et al.  Oxidation of 3,6-dioxa-1,8-octanedithiol by platinum(IV) anticancer prodrug and model complex: kinetic and mechanistic studies. , 2012, The journal of physical chemistry. B.

[292]  J. Aldrich-Wright,et al.  Synthesis of DNA-sequence-selective hairpin polyamide platinum complexes. , 2007, Chemistry.

[293]  Seann P. Mulcahy,et al.  Discovery of a strongly apoptotic ruthenium complex through combinatorial coordination chemistry. , 2010, Dalton transactions.

[294]  C. Biot,et al.  Structure–activity relationships of 4-N-substituted ferroquine analogues: Time to re-evaluate the mechanism of action of ferroquine , 2009 .

[295]  L. Ji,et al.  Platinum(II)-triarylpyridines complexes with electropositive pendants as efficient G-quadruplex binders. , 2011, Dalton transactions.

[296]  J. Furrer,et al.  Anticancer activity of opened arene ruthenium metalla-assemblies. , 2010, Dalton transactions.

[297]  Amanda J. Pickard,et al.  Replacement of a thiourea with an amidine group in a monofunctional platinum-acridine antitumor agent. Effect on DNA interactions, DNA adduct recognition and repair. , 2011, Molecular pharmaceutics.

[298]  P. Dyson,et al.  Synthesis, Characterization and Anticancer Activity of Porphyrin-Containing Organometallic Cubes , 2010 .

[299]  P. Scheurich,et al.  Tumor necrosis factor signaling , 2003, Cell Death and Differentiation.

[300]  Jim A. Thomas,et al.  Differentiating quadruplexes: binding preferences of a luminescent dinuclear ruthenium(II) complex with four-stranded DNA structures. , 2010, Organic & biomolecular chemistry.

[301]  B. Keppler,et al.  Biomolecule binding vs. anticancer activity: reactions of Ru(arene)[(thio)pyr-(id)one] compounds with amino acids and proteins. , 2012, Journal of inorganic biochemistry.

[302]  Quan Hao,et al.  Iron and bismuth bound human serum transferrin reveals a partially-opened conformation in the N-lobe , 2012, Scientific Reports.

[303]  P. Dyson,et al.  Metal-based antitumour drugs in the post genomic era. , 2006, Dalton transactions.

[304]  P. Sadler,et al.  Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: novel recognition mechanisms. , 2003, Journal of the American Chemical Society.

[305]  N. Farrell,et al.  Kinetic and equilibria studies of the aquation of the trinuclear platinum phase II anticancer agent [(trans-PtCl(NH(3))(2))(2)(mu-trans-Pt(NH(3))(2)(NH(2)(CH(2))(6)NH(2))(2))](4+) (BBR3464). , 2002, Inorganic chemistry.

[306]  B. Therrien,et al.  Anticancer activity of tetracationic arene ruthenium metalla-cycles. , 2011, Dalton transactions.

[307]  N. Farrell,et al.  BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[308]  M. Wright,et al.  Solution structural study of a DNA duplex containing the guanine-N7 adduct formed by a cytotoxic platinum-acridine hybrid agent. , 2005, Biochemistry.

[309]  Hong Liang,et al.  Synthesis, characterization, and in vitro antitumor properties of gold(III) compounds with the traditional Chinese medicine (TCM) active ingredient liriodenine , 2012, JBIC Journal of Biological Inorganic Chemistry.

[310]  P. Cramer,et al.  Mechanism of transcriptional stalling at cisplatin-damaged DNA , 2007, Nature Structural &Molecular Biology.

[311]  S. Lippard,et al.  2.4 A crystal structure of an oxaliplatin 1,2-d(GpG) intrastrand cross-link in a DNA dodecamer duplex. , 2001, Inorganic chemistry.

[312]  E. De Clercq,et al.  CXCR4 chemokine receptor antagonists: nickel(II) complexes of configurationally restricted macrocycles. , 2012, Dalton transactions.

[313]  C. Biot,et al.  Opening up the advantages of the ruthenocenic bioprobes of ferroquine: distribution and localization in Plasmodium falciparum-infected erythrocytes. , 2012, Metallomics : integrated biometal science.

[314]  A. Wang,et al.  Structure and isomerization of an intrastrand cisplatin-cross-linked octamer DNA duplex by NMR analysis. , 1995, Biochemistry.

[315]  A. Riyasdeen,et al.  Interaction of rac-[M(diimine)3]2+ (M=Co, Ni) complexes with CT DNA: role of 5,6-dmp ligand on DNA binding and cleavage and cytotoxicity. , 2011, Dalton transactions.

[316]  C. S. Allardyce,et al.  [Ru(η6-p-cymene)Cl2(pta)] (pta = 1,3,5-triaza-7-phosphatricyclo- [3.3.1.1]decane): a water soluble compound that exhibits pH dependent DNA binding providing selectivity for diseased cells , 2001 .

[317]  S. Schneider,et al.  Crystal structure of a cisplatin-(1,3-GTG) cross-link within DNA polymerase eta. , 2010, Angewandte Chemie.

[318]  S. Govindasamy,et al.  Effect of sodium molybdate on the status of lipids, lipid peroxidation and antioxidant systems in alloxan-induced diabetic rats. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[319]  S. Lippard,et al.  Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin , 1995, Nature.

[320]  B. Howerton,et al.  Strained ruthenium complexes are potent light-activated anticancer agents. , 2012, Journal of the American Chemical Society.

[321]  Li Feng,et al.  Dual anticancer activity in a single compound: visible-light-induced apoptosis by an antiangiogenic iridium complex. , 2012, Chemical communications.

[322]  K. P. Kepp,et al.  Bioinorganic chemistry of Alzheimer's disease. , 2012, Chemical reviews.

[323]  I. Ott,et al.  Synthesis, Spectroscopic, Anticancer, and Antimicrobial Properties of Some Metal(II) Complexes of (Substituted) Nitrophenol Schiff Base , 2012 .

[324]  C. Rogier,et al.  The antimalarial ferroquine: role of the metal and intramolecular hydrogen bond in activity and resistance. , 2011, ACS chemical biology.

[325]  G. Mao,et al.  Enhanced Anti-Diabetic Activity of a Combination of Chromium(III) Malate Complex and Propolis and its Acute Oral Toxicity Evaluation , 2012, Biological Trace Element Research.

[326]  G. Leclercq,et al.  The first organometallic selective estrogen receptor modulators (SERMs) and their relevance to breast cancer. , 2004, Current medicinal chemistry.

[327]  F. Murad,et al.  Nitric oxide (NO): Biogeneration, regulation, and relevence to human diseases , 2003 .

[328]  P. Sadler,et al.  Functionalization of osmium arene anticancer complexes with (poly)arginine: effect on cellular uptake, internalization, and cytotoxicity. , 2011, Bioconjugate chemistry.

[329]  P. Faller,et al.  A bioinorganic view of Alzheimer's disease: when misplaced metal ions (re)direct the electrons to the wrong target. , 2012, Chemistry.

[330]  S. Knapp,et al.  Crystal Structure of the PIM2 Kinase in Complex with an Organoruthenium Inhibitor , 2009, PloS one.

[331]  P. Sadler,et al.  A potent trans-diimine platinum anticancer complex photoactivated by visible light. , 2010, Angewandte Chemie.

[332]  Stefania Girotto,et al.  Reduced Affinity for Isoniazid in the S315T Mutant ofMycobacterium tuberculosis KatG Is a Key Factor in Antibiotic Resistance* , 2003, The Journal of Biological Chemistry.

[333]  W. Antholine,et al.  The intracellular redox stress caused by hexavalent chromium is selective for proteins that have key roles in cell survival and thiol redox control. , 2011, Toxicology.

[334]  Z. Suo,et al.  Structural insight into dynamic bypass of the major cisplatin‐DNA adduct by Y‐family polymerase Dpo4 , 2010, The EMBO journal.

[335]  Rebekah Cook,et al.  Novel platinum(II)-based anticancer complexes and molecular hosts as their drug delivery vehicles. , 2007, Dalton transactions.

[336]  N. Farrell,et al.  Competitive reactions of interstrand and intrastrand DNA-Pt adducts: A dinuclear-platinum complex preferentially forms a 1,4-interstrand cross-link rather than a 1,2 intrastrand cross-link on binding to a GG 14-mer duplex. , 2003, Chemistry.

[337]  K. Fromm,et al.  Rings, chains and helices: new antimicrobial silver coordination compounds with (iso-)nicotinic acid derivatives. , 2013, Dalton transactions.

[338]  S. Lippard,et al.  Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA. , 1985, Biochimica et biophysica acta.

[339]  P. Sadler,et al.  The contrasting activity of iodido versus chlorido ruthenium and osmium arene azo- and imino-pyridine anticancer complexes: control of cell selectivity, cross-resistance, p53 dependence, and apoptosis pathway. , 2013, Journal of medicinal chemistry.

[340]  P. Sadler,et al.  Photocytotoxic trans-diam(m)ine platinum(IV) diazido complexes more potent than their cis isomers. , 2010, Chemical research in toxicology.

[341]  Peter J. Tonge,et al.  The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: Adduct affinity and drug resistance , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[342]  B. Therrien,et al.  Host–Guest Chemistry in the Hexanuclear (Arene)ruthenium Metalla‐Prismatic Cage [Ru6(p‐cymene)6(tpt)2(dhnq)3]6+ , 2009 .

[343]  A. Bergamo,et al.  Ruthenium complexes can target determinants of tumour malignancy. , 2007, Dalton transactions.

[344]  Eric Meggers,et al.  PIM1 kinase as a target for cancer therapy , 2012, Expert opinion on investigational drugs.

[345]  J. Fitzpatrick,et al.  Manipulating the Ability of Substituted Titanocene Derivatives to Induce Apoptosis in Castrate-Resistant Prostate Cancer Cells , 2012 .

[346]  P. Dyson,et al.  Encapsulation of inorganic and organic guest molecules into an organometallic hexacationic arene osmium metalla-prism: Synthesis, characterisation and anticancer activity , 2012 .

[347]  Zou,et al.  First Crystal Structure of a Medicinally Relevant Gold Protein Complex: Unexpected Binding of , 2000, Angewandte Chemie.

[348]  C. McKnight,et al.  Zinc and copper bind to unique sites of histatin 5 , 2001, FEBS letters.

[349]  J. Bandow,et al.  New Ways of Killing the Beast: Prospects for Inorganic–Organic Hybrid Nanomaterials as Antibacterial Agents , 2009, Chembiochem : a European journal of chemical biology.

[350]  G. Deacon,et al.  Remarkable in vitro bactericidal activity of bismuth(III) sulfonates against Helicobacter pylori. , 2012, Dalton transactions.

[351]  R. Stenkamp,et al.  X-ray structure and designed evolution of an artificial transfer hydrogenase. , 2008, Angewandte Chemie.

[352]  G. Süss-Fink.  Arene ruthenium complexes as anticancer agents. , 2010, Dalton transactions.

[353]  G. Süss-Fink,et al.  Permanent Encapsulation or Host–Guest Behavior of Aromatic Molecules in Hexanuclear Arene Ruthenium Prisms , 2010 .

[354]  P. Sadler,et al.  The contrasting chemical reactivity of potent isoelectronic iminopyridine and azopyridine osmium(II) arene anticancer complexes , 2012 .

[355]  N. Shahabadi,et al.  DNA interaction studies of a platinum(II) complex containing L-histidine and 1,10-phenanthroline ligands. , 2012, DNA and cell biology.

[356]  M. Saunders,et al.  Visualising gold inside tumour cells following treatment with an antitumour gold(I) complex. , 2011, Metallomics : integrated biometal science.

[357]  A. Eastman.  Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum(II) and cis-dichloro(ethylenediamine)platinum(II). , 1983, Biochemistry.

[358]  J. Furrer,et al.  Investigation of the reactivity between a ruthenium hexacationic prism and biological ligands. , 2012, Inorganic chemistry.

[359]  G. Jaouen,et al.  Targeted therapy vs. DNA-adduct formation-guided design: thoughts about the future of metal-based anticancer drugs. , 2012, Dalton transactions.

[360]  D. Osella,et al.  On the mechanism of the antitumor activity of ferrocenium derivatives , 2000 .

[361]  M. Gresser,et al.  Inhibition of phosphatase and sulfatase by transition-state analogues. , 1988, Biochemistry.

[362]  Hongzhe Sun,et al.  Tracking bismuth antiulcer drug uptake in single Helicobacter pylori cells. , 2011, Journal of the American Chemical Society.

[363]  A. Miele,et al.  On the mechanism and rate of gold incorporation into thiol-dependent flavoreductases. , 2012, Journal of inorganic biochemistry.

[364]  P. Dyson,et al.  Excellent correlation between drug release and portal size in metalla-cage drug-delivery systems. , 2011, Chemistry.

[365]  W. Berger,et al.  Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells , 2005, Journal of Cancer Research and Clinical Oncology.

[366]  P. Sadler,et al.  Organometallic half-sandwich iridium anticancer complexes. , 2011, Journal of medicinal chemistry.

[367]  H. Toft,et al.  Synthesis, characterization, and DNA binding properties of a series of Ru, Pt mixed-metal complexes. , 2003, Inorganic chemistry.

[368]  M. Gore,et al.  Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. , 2007, Journal of Clinical Oncology.

[369]  A. Casini,et al.  Biophysical characterisation of adducts formed between anticancer metallodrugs and selected proteins: new insights from X-ray diffraction and mass spectrometry studies. , 2008, Journal of inorganic biochemistry.

[370]  M. Surin,et al.  A rigid dinuclear ruthenium(II) complex as an efficient photoactive agent for bridging two guanine bases of a duplex or quadruplex oligonucleotide. , 2010, Chemistry.

[371]  A. Casini,et al.  New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications , 2008, FEBS letters.

[372]  R. Sun,et al.  Targeting metabolism with arsenic trioxide and dichloroacetate in breast cancer cells , 2011, Molecular Cancer.

[373]  P. Dyson,et al.  Enhancement of cytotoxicity by combining pyrenyl-dendrimers and arene ruthenium metallacages. , 2012, Inorganic chemistry.

[374]  L. Pendyala,et al.  Clinical development of iproplatin (CHIP). , 1986, Drugs under experimental and clinical research.

[375]  K. Antman,et al.  Introduction: the history of arsenic trioxide in cancer therapy. , 2001, The oncologist.

[376]  L. Chacón-García,et al.  The search of DNA-intercalators as antitumoral drugs: what it worked and what did not work. , 2005, Current medicinal chemistry.

[377]  M. G. Monti,et al.  Characterization of the cell growth inhibitory effects of a novel DNA-intercalating bipyridyl-thiourea-Pt(II) complex in cisplatin-sensitive and—resistant human ovarian cancer cells , 2011, Investigational New Drugs.

[378]  R. Abagyan,et al.  Stabilization of G-quadruplex DNA with platinum(II) Schiff base complexes: luminescent probe and down-regulation of c-myc oncogene expression. , 2009, Chemistry.